EA025252B1
(ru)
|
2010-07-22 |
2016-12-30 |
Гайлид Сайэнсиз, Инк. |
Способы и соединения для лечения вирусных инфекций paramyxoviridae
|
KR20160148715A
(ko)
*
|
2014-05-13 |
2016-12-26 |
에프. 호프만-라 로슈 아게 |
B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온
|
TWI687432B
(zh)
|
2014-10-29 |
2020-03-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
US9637485B2
(en)
*
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
EP3256471B1
(en)
*
|
2015-02-11 |
2018-12-12 |
F. Hoffmann-La Roche AG |
Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
EP3292120B1
(en)
|
2015-05-04 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
US10179131B2
(en)
|
2015-07-13 |
2019-01-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
WO2017016921A1
(en)
*
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
WO2017017042A1
(en)
|
2015-07-27 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
CN107835813B
(zh)
|
2015-07-28 |
2020-04-24 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的6,7-二氢吡啶并[2,1-a]酞嗪-2-酮类化合物
|
EA038141B1
(ru)
|
2015-09-16 |
2021-07-13 |
Джилид Сайэнс, Инк. |
Способы лечения вирусных инфекций arenaviridae и coronaviridae
|
ES2897913T3
(es)
|
2016-02-19 |
2022-03-03 |
Novartis Ag |
Compuestos de piridona tetracíclicos como antivirales
|
BR112018067964B1
(pt)
|
2016-03-07 |
2024-01-16 |
Enanta Pharmaceuticals, Inc |
Composto, composição farmacêutica que o compreende e uso do referido composto
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
WO2017205078A1
(en)
|
2016-05-27 |
2017-11-30 |
Gilead Sciences, Inc. |
Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
|
EP3468561A4
(en)
|
2016-06-10 |
2019-12-04 |
Enanta Pharmaceuticals, Inc. |
ANTIVIRAL AGENTS AGAINST HEPATITIS B
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
MA45496A
(fr)
*
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
JP7034133B2
(ja)
*
|
2016-07-14 |
2022-03-11 |
エフ.ホフマン-ラ ロシュ アーゲー |
感染性疾患の処置のためのカルボキシ 6,7-ジヒドロ-4H-ピラゾロ[1,5-a]ピラジン化合物
|
CN107759585A
(zh)
*
|
2016-07-29 |
2018-03-06 |
银杏树药业(苏州)有限公司 |
一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
|
EP3490987B1
(en)
|
2016-07-29 |
2022-09-21 |
Guangzhou Lupeng Pharmaceutical Company Ltd. |
Novel therapeutic agents for the treatment of hbv infection
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
WO2018041873A1
(en)
*
|
2016-09-01 |
2018-03-08 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
CN109923106B
(zh)
|
2016-09-02 |
2022-09-13 |
吉利德科学公司 |
toll样受体调节剂化合物
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
MX2019004349A
(es)
|
2016-10-14 |
2019-09-26 |
Prec Biosciences Inc |
Meganucleasas manipuladas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
WO2018083106A1
(en)
|
2016-11-03 |
2018-05-11 |
F. Hoffmann-La Roche Ag |
Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
WO2018083136A1
(en)
|
2016-11-03 |
2018-05-11 |
F. Hoffmann-La Roche Ag |
Novel tetrahydroisoquinolines and terahydronaphthyridines for the treatment and prophylaxis of hepatitis b virus infection
|
CN110088104B
(zh)
|
2016-11-03 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物
|
KR102522060B1
(ko)
*
|
2016-11-07 |
2023-04-14 |
아뷰터스 바이오파마 코포레이션 |
치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
CN106810548B
(zh)
|
2017-01-13 |
2019-02-15 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
TWI820984B
(zh)
|
2017-01-31 |
2023-11-01 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
ES2874656T3
(es)
*
|
2017-02-23 |
2021-11-05 |
Fujian Cosunter Pharmaceutical Co Ltd |
Compuesto tricíclico y aplicaciones del mismo
|
JP6824434B2
(ja)
|
2017-03-14 |
2021-02-03 |
ギリアード サイエンシーズ, インコーポレイテッド |
ネココロナウイルス感染を処置する方法
|
US11098010B2
(en)
|
2017-03-21 |
2021-08-24 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
KR20190141747A
(ko)
|
2017-05-01 |
2019-12-24 |
길리애드 사이언시즈, 인코포레이티드 |
(S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
|
CN108530449B
(zh)
*
|
2017-05-22 |
2021-05-07 |
河南春风医药科技有限公司 |
用于治疗或预防乙型肝炎病毒感染的化合物及其制备方法与应用
|
CN110066278B
(zh)
*
|
2017-06-01 |
2021-06-08 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
CA3077489A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
EP3675637A4
(en)
|
2017-08-28 |
2021-05-19 |
Enanta Pharmaceuticals, Inc. |
ANTIVIRAL AGENTS AGAINST HEPATITIS B
|
JP7248665B2
(ja)
*
|
2017-10-05 |
2023-03-29 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
化学化合物
|
CR20200205A
(es)
|
2017-10-16 |
2020-06-28 |
Hoffmann La Roche |
MOLECULA DE ACIDOS NUCLEICOS PARA LA REDUCCIÒN DEL ARNm DE PAPD5 Y PAPD7 EN EL TRATAMIENTO DE LA INFECCIÒN DE LA HEPATITIS B
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
WO2019113173A1
(en)
|
2017-12-06 |
2019-06-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
WO2019113175A1
(en)
|
2017-12-06 |
2019-06-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
EP3728282B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
EP3728266A1
(en)
|
2017-12-20 |
2020-10-28 |
Novartis AG |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
JP7037667B2
(ja)
|
2017-12-20 |
2022-03-16 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. |
Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
|
EA038176B9
(ru)
*
|
2018-01-04 |
2021-09-07 |
Фуцзянь Косантер Фармасьютикал Ко., Лтд. |
Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в
|
WO2019143902A2
(en)
|
2018-01-22 |
2019-07-25 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
PE20210640A1
(es)
|
2018-02-13 |
2021-03-23 |
Gilead Sciences Inc |
Inhibidores pd-1/pd-l1
|
PL3759109T3
(pl)
|
2018-02-26 |
2024-03-04 |
Gilead Sciences, Inc. |
Podstawione związki pirolizyny jako inhibitory replikacji hbv
|
JP2021514982A
(ja)
|
2018-02-28 |
2021-06-17 |
ノバルティス アーゲー |
インドール−2−カルボニル化合物及びb型肝炎治療のためのそれらの使用
|
WO2019177937A1
(en)
|
2018-03-12 |
2019-09-19 |
Arbutus Biopharma, Inc. |
Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
|
US10729688B2
(en)
|
2018-03-29 |
2020-08-04 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
US11505551B2
(en)
|
2018-04-12 |
2022-11-22 |
Arbutus Biopharma Corporation |
Methods for preparing substituted pyridinone-containing tricyclic compounds
|
JP7242702B2
(ja)
|
2018-04-19 |
2023-03-20 |
ギリアード サイエンシーズ, インコーポレイテッド |
Pd-1/pd-l1阻害剤
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
KR102585973B1
(ko)
|
2018-07-03 |
2023-10-10 |
에프. 호프만-라 로슈 아게 |
타우 발현을 조절하기 위한 올리고뉴클레오티드
|
UA126421C2
(uk)
|
2018-07-13 |
2022-09-28 |
Гіліад Сайєнсіз, Інк. |
Інгібітори pd-1/pd-l1
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯,其類似物及使用其之方法
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
US10865211B2
(en)
|
2018-09-21 |
2020-12-15 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
EP3856740A4
(en)
|
2018-09-30 |
2021-12-15 |
Sunshine Lake Pharma Co., Ltd. |
CONDENSED TETRACYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
|
CA3117199C
(en)
|
2018-10-24 |
2024-03-19 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
JP7273172B2
(ja)
|
2018-10-31 |
2023-05-12 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hpk1阻害活性を有する置換6-アザベンゾイミダゾール化合物
|
CR20210215A
(es)
|
2018-10-31 |
2021-06-17 |
Gilead Sciences Inc |
Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
|
EP3883570A4
(en)
|
2018-11-21 |
2022-07-13 |
Enanta Pharmaceuticals, Inc. |
FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
CN114014854B
(zh)
*
|
2019-01-08 |
2023-04-07 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
CA3129011C
(en)
|
2019-03-07 |
2023-12-19 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
JP7350871B2
(ja)
|
2019-03-07 |
2023-09-26 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. |
2’3’-環状ジヌクレオチドおよびそのプロドラッグ
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
US11236111B2
(en)
|
2019-06-03 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
WO2020247575A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
WO2020247561A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
CN114245807A
(zh)
|
2019-06-25 |
2022-03-25 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
US11738019B2
(en)
|
2019-07-11 |
2023-08-29 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
US20220296619A1
(en)
|
2019-08-19 |
2022-09-22 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
WO2021055425A2
(en)
|
2019-09-17 |
2021-03-25 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
US11497808B2
(en)
|
2019-09-30 |
2022-11-15 |
Gilead Sciences, Inc. |
HBV vaccines and methods treating HBV
|
WO2021113765A1
(en)
|
2019-12-06 |
2021-06-10 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
AU2020412875A1
(en)
|
2019-12-24 |
2022-06-23 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
AU2021214911A1
(en)
|
2020-01-27 |
2022-07-21 |
Gilead Sciences, Inc. |
Methods for treating SARS CoV-2 infections
|
TWI785528B
(zh)
|
2020-03-12 |
2022-12-01 |
美商基利科學股份有限公司 |
1’-氰基核苷之製備方法
|
US11802125B2
(en)
|
2020-03-16 |
2023-10-31 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
EP4121437A1
(en)
|
2020-03-20 |
2023-01-25 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
US11701372B2
(en)
|
2020-04-06 |
2023-07-18 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
|
JP2023526346A
(ja)
*
|
2020-05-15 |
2023-06-21 |
福建▲広▼生中霖生物科技有限公司 |
三環式化合物を含む組み合わせ及びhbv治療薬物の製造におけるその使用
|
JP2023528810A
(ja)
|
2020-05-29 |
2023-07-06 |
ギリアード サイエンシーズ, インコーポレイテッド |
レムデシビル治療方法
|
TWI819321B
(zh)
|
2020-06-24 |
2023-10-21 |
美商基利科學股份有限公司 |
1'-氰基核苷類似物及其用途
|
US20230303599A1
(en)
|
2020-08-07 |
2023-09-28 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
CN111943946B
(zh)
*
|
2020-08-19 |
2022-07-01 |
中国医学科学院医药生物技术研究所 |
含有氮杂环片段的二氢喹嗪酮羧酸类化合物及其应用
|
CR20230100A
(es)
|
2020-08-24 |
2023-04-28 |
Gilead Sciences Inc |
Compuestos fosfolípidos y usos de los mismos
|
EP4204421B1
(en)
|
2020-08-27 |
2024-05-15 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
TW202344257A
(zh)
|
2020-10-16 |
2023-11-16 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
AU2022274607A1
(en)
|
2021-05-13 |
2023-11-16 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
WO2022251318A1
(en)
|
2021-05-26 |
2022-12-01 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
|
EP4359411A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CN117480155A
(zh)
|
2021-06-23 |
2024-01-30 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
AU2022328698A1
(en)
|
2021-08-18 |
2024-02-01 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
US20230322813A1
(en)
|
2022-03-02 |
2023-10-12 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
EP4320128A1
(en)
|
2022-03-02 |
2024-02-14 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
WO2023168254A1
(en)
|
2022-03-03 |
2023-09-07 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
US20240199676A1
(en)
|
2022-03-03 |
2024-06-20 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
US20240009220A1
(en)
|
2022-06-06 |
2024-01-11 |
Gilead Sciences, Inc. |
Methods for treatment of viral infections
|
WO2024006376A1
(en)
|
2022-06-29 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
US20240043466A1
(en)
|
2022-06-30 |
2024-02-08 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|